Mundipharma Writes Cidara a $30 Million Check

Cidara Therapeutics and Mundipharma Form Strategic Partnership to Develop and Commercialize Rezafungin
Published: Sep 03, 2019

Sept. 3, 2019 10:00 UTC
Collaboration combines strengths to develop and commercialize life-saving antifungal treatment and prophylaxis, an area of high unmet medical need

* Mundipharma acquires exclusive rights to develop and commercialize rezafungin in all markets outside of the United States and Japan, which will be retained by Cidara

* Cidara to receive upfront payment of $30 million and equity investment of $9 million, co-development funding, development milestones and tiered royalty stream

* Total transaction value could exceed $568 million

This is what it looks like when Mundipharam enters a Strategic Partnership with a company.

https://www.biospace.com/article/releases/cid...zafungin-/